Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-18
2007-09-18
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S228000
Reexamination Certificate
active
10508043
ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
REFERENCES:
patent: 4006149 (1977-02-01), Bonnemann et al.
patent: 4011328 (1977-03-01), Pinhas et al.
patent: 4169951 (1979-10-01), Beschke et al.
patent: 4533666 (1985-08-01), Matsumoto et al.
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5077142 (1991-12-01), Sakun et al.
patent: 5081122 (1992-01-01), Ward
patent: 5112820 (1992-05-01), Ward
patent: 5217982 (1993-06-01), Fink et al.
patent: 5248687 (1993-09-01), Hayase et al.
patent: 5292734 (1994-03-01), Levin et al.
patent: 5380700 (1995-01-01), Miyazaki et al.
patent: 5492915 (1996-02-01), Dereu et al.
patent: 5593994 (1997-01-01), Batt et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5672609 (1997-09-01), Bryant et al.
patent: 5686470 (1997-11-01), Weier et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5750708 (1998-05-01), Bryant et al.
patent: 5861419 (1999-01-01), Dube et al.
patent: 5916905 (1999-06-01), Weier et al.
patent: 5932586 (1999-08-01), Batt et al.
patent: 6001843 (1999-12-01), Dube et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6127386 (2000-10-01), Lin et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 0308020 (1989-03-01), None
patent: 444533 (1991-09-01), None
patent: 0363818 (1994-04-01), None
patent: 0359547 (1996-01-01), None
patent: 658546 (2001-05-01), None
patent: 1328269 (2004-05-01), None
patent: 1078920 (2004-07-01), None
patent: 1395110 (1973-09-01), None
patent: 1401038 (1995-07-01), None
patent: 2323841 (1998-10-01), None
patent: 05-331164 (1993-12-01), None
patent: 6-16638 (1994-01-01), None
patent: 07-247214 (1995-09-01), None
patent: 2001-247548 (2001-09-01), None
patent: WO 92/01675 (1992-02-01), None
patent: WO 92/02513 (1992-02-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 96/24584 (1996-08-01), None
patent: WO 96/41625 (1996-12-01), None
patent: WO 97/04778 (1997-02-01), None
patent: WO 97/29079 (1997-08-01), None
patent: WO 98/03484 (1998-01-01), None
patent: WO 98/31227 (1998-07-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO 99/59635 (1999-11-01), None
patent: WO 00/10967 (2000-03-01), None
patent: WO 00/10968 (2000-03-01), None
patent: WO 00/37107 (2000-06-01), None
patent: WO 00/38786 (2000-07-01), None
patent: WO 01/36387 (2001-05-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO 02/055502 (2002-07-01), None
patent: WO 02/076945 (2002-10-01), None
patent: WO2002096516 (2002-12-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/063781 (2003-08-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/084930 (2003-10-01), None
patent: WO 03/084943 (2003-10-01), None
patent: WO 03/086394 (2003-10-01), None
patent: WO 2004/012671 (2004-02-01), None
patent: WO 2004/029026 (2004-04-01), None
patent: WO 2004/029027 (2004-04-01), None
patent: WO 2004/029204 (2004-04-01), None
patent: WO 2004/111039 (2004-12-01), None
patent: WO 2005/000817 (2005-01-01), None
patent: WO 2005/016286 (2005-02-01), None
Konno et al. Yakugaku Zasshi (1993), 113(1), 40-52; CAPLUS Accession No. 1993:234009)).
Barth, Exp. Opin. Ther. Patents, vol. 8 (1998), pp. 301-313, “Cannabinoid receptor agonists and antagonists”.
Xiang et al., Ann. Rep. Med. Chem., A. Doherty, ed., Academic Press, NY (1999), vol. 34, pp. 199-208, “Chapter 20. Pharmacology of cannabinoid receptor agonists and antagonists”.
Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, “Recent advances in cannabinoid receptor agonists and antagonists”.
Piomelli et al., Trends in Pharm. Sci., vol. 21 (2000), pp. 218-224, “The endocannabinoid system as a target for therapeutic drugs”.
Sano et al., Chem. Pharm. Bull., vol. 38 (1990), pp. 3283-3295, “Dioxopyrorolines. XLIX. Synthesis of azatropolones via photocycloaddition of 5-aryl-4-ethoxycarbonyl-1H-pyrrole-2,3-diones to acetylenes and ethylenes”.
Van Aken et al., Tetra. Letters, vol. 33 (1992), pp. 2713-2716, “Functionalization in positino 3 of 3,5-dichloro-2H-1,4-oxazin-2-ones”.
Brown et al., Tetra. Letters, vol. 33 (1992), pp. 3787-3790 “Retro-Diels-Alder fragmentation of 2,5,6-triphenyl-13,4-didehydropyridine generated by flash vacuum pyrolysis at 900 degree C”.
Troschuetz et al., Arch. Pharm., vol. 327 (1994), pp. 33-40, “Synthesis of substituted 2-aminonicotinonitriles”.
Kagabu et al., J. Chem. Soc., vol. 6 (1994), pp. 739-751, “Thermal rearrangement of N-arylmethyl- and N-alkyl-2,2-dihalogenocyclopropyl imines”.
Hitzler et al., Synthesis, vol. 5 (1994), vol. 5, pp. 509-515, “On the reaction of 1,3-dichloro-2-azoniaallene salts with olefins and diphenylacetylene”.
Nehl, Chem. Ber., vol. 127 (1994), pp. 2535-2537, “(.eta.3-Allyl)(.eta.5-pentamethylcyclopentadienyl)cobalt- a selective catalyst for the pyridine synthesis”.
Tanaka et al., Chem. Pharm. Bull., vol. 42 (1994), pp. 1828-1834, “Studies on anti-platelet agents.”
Palacios et al., Tetra. Letters, vol. 37 (1996), pp. 4577-4580, “A one-pot synthesis of of polysubstituted pyridines from metalated alkylphosphonates, nitriles and .alpha., .beta.-unsaturated ketones . . . ”.
Paparin et al., J. Heterocycl. Chem., vol. 47 (2000), pp. 411-418, “Synthesis of 2,5-bisarylpyridines by [4 +2] cycloaddition of 2,4-bisaryl-2-aza-1,3-butadienes with electron-poor dienophiles . . . ”.
Marcoux et al., Organic Letters, vol. 2 (2000), pp. 2339-2341, “Annulation of keones with vinamidinium hexafluorophosphate salts: An efficient preparation of trisubstituted pyridines”.
Palacios et al., Tetrahedron, vol. 56 (2000), pp. 6319-6330, “Synthesis and reactivity of imines derived from bisphosphonates and 3-phosphorylated 2-aza-1,3-dienes”.
Palacios et al., Eur. J. Org. Chem., vol. 11 (2001), pp. 2115-2122, “Cycloaddition reactions of neutral 2-azadienes with enamines—regiospecific synthesis of highly substituted dihydropyridines and pyridines”.
Yamamoto et al., Chem. Pharm. Bull., vol. 33 (1985), pp. 975-981, “1,3-Oxazines and related compounds”.
Gruseck et al., Tetradron Letters, vol. 28 (1987), pp. 6027-6030, “The remarkable reactivity of 2-alkylideneimidazolidines in inverse Diels-Alder reactions”.
Tsuda et al., Heterocycles, vol. 12 (1979), pp. 1423-1426, “Establishment of the structures of azatropolones and their rearrangement products by X-ray analysis”.
Van Aken et al., Tetrahedron, vol. 50 (1994), pp. 5211-5224, “The synthesis of 3-functionalized 5-chloro-6-methyl2H-1,4-oxazin-2-ones and of pyridines from cycloaddition-elimination . . . ”.
Konno et al., Yakugaku Zasshi, vol. 113 (1993), pp. 40-52, “Studies on as-triazine derivatives.”
Debenham John S.
Finke Paul E.
Meurer Laura C.
Toupence Richard B.
Walsh Thomas F.
Brown Beerbel R.
Chandrakumar Nizal S.
Fitch Catherine D.
Merck & Co. , Inc.
Seaman D. Margaret
LandOfFree
Substituted 2,3-diphenyl pyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2,3-diphenyl pyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2,3-diphenyl pyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731999